

# Jonathan Strosberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1631425/publications.pdf>

Version: 2024-02-01

84  
papers

7,939  
citations

101543

36  
h-index

62596

80  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. <i>Current Oncology</i> , 2022, 29, 510-515.	2.2	8
2	Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. <i>Cancers</i> , 2022, 14, 1428.	3.7	6
3	Multiple Tumors in a Young Patient. <i>Gastroenterology</i> , 2022, 163, e13-e15.	1.3	0
4	A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	2.8	30
5	Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2966.	3.7	9
6	Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 69-72.	5.0	30
7	Sensitivity and Specificity of the NETest: A Validation Study. <i>Neuroendocrinology</i> , 2021, 111, 580-585.	2.5	6
8	Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. <i>Oncologist</i> , 2021, 26, 115-119.	3.7	15
9	Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102141.	7.7	43
10	Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12936.	2.6	3
11	An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). <i>Current Treatment Options in Oncology</i> , 2021, 22, 28.	3.0	3
12	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.	2.9	7
13	Markers of Systemic Inflammation in Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 130-137.	1.1	6
14	Somatostatin receptor radionuclide therapy in neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, R81-R93.	3.1	9
15	Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 161-172.	3.1	52
16	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
17	A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 1803-1808.	6.4	20
18	A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. <i>Cancer</i> , 2021, 127, 3194-3201.	4.1	48

#	ARTICLE	IF	CITATIONS
19	Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2021, 50, 513-515.	1.1	5
20	Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1321-1321.	5.0	1
21	Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1669-1671.	5.0	5
22	Chemotherapy in Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 4872.	3.7	13
23	<sup>177</sup> Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1752-1763.	10.7	195
24	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 377-383.	2.5	15
25	Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 584-591.	0.5	7
26	Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. <i>Oncologist</i> , 2020, 25, e48-e52.	3.7	42
27	Molecular imaging and radionuclide therapy of neuroendocrine tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 16-21.	2.3	7
28	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.	2.4	23
29	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , 2020, 21, e431-e443.	10.7	51
30	Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.	1.1	2
31	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	5.0	6
32	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup> Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
33	Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. <i>Chest</i> , 2020, 158, 401-405.	0.8	15
34	Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 54-54.	3.0	29
35	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
36	What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. <i>Oncotarget</i> , 2020, 11, 3751-3752.	1.8	2

#	ARTICLE	IF	CITATIONS
37	<sup>177</sup> Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1023-1031.	3.0	60
38	TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist, 2019, 24, 1446-1452.	3.7	19
39	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. Journal of Nuclear Medicine, 2019, 60, 721-727.	5.0	15
40	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	3.3	26
41	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
42	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Research Protocols, 2019, 8, e11545.	1.0	27
43	Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: <sup>177</sup> Lu-RADIANT lung subgroup analysis. Cancer Science, 2018, 109, 174-181.	3.9	72
44	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 292-299.	3.8	9
45	Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup> Lu-Dotatate in the Phase III NETTER-1 Trial. Journal of Clinical Oncology, 2018, 36, 2578-2584.	1.6	276
46	Gastroenteropancreatic Neuroendocrine Tumors. Ca-A Cancer Journal for Clinicians, 2018, 68, 471-487.	329.8	378
47	Peptide Receptor Radiotherapy Comes of Age. Endocrinology and Metabolism Clinics of North America, 2018, 47, 615-625.	3.2	7
48	Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 125-135.	27.0	2,206
49	Radionuclide Therapy for Neuroendocrine Tumors. Current Oncology Reports, 2017, 19, 9.	4.0	113
50	<sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 1390-1392.	27.0	35
51	Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Current Treatment Options in Oncology, 2017, 18, 14.	3.0	52
52	Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Current Opinion in Oncology, 2016, 28, 359-366.	2.4	28
53	Surgical Treatment of an Isolated Metastatic Myocardial Neuroendocrine Tumor. Annals of Thoracic Surgery, 2016, 101, 747-749.	1.3	11
54	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	1.9	83

#	ARTICLE	IF	CITATIONS
55	A phase II study of axitinib in advanced neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 411-418.	3.1	38
56	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2016, 387, 968-977.	13.7	962
57	Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 1-9.	3.1	76
58	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 1551-1556.	1.6	110
59	The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Drugs</i> , 2015, 75, 847-858.	10.9	42
60	Outcomes of Therasphere Radioembolization for Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2015, 14, 146-153.	2.3	32
61	Consensus on biomarkers for neuroendocrine tumour disease. <i>Lancet Oncology, The</i> , 2015, 16, e435-e446.	10.7	217
62	Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. <i>Gastroenterology</i> , 2015, 149, 33-34.	1.3	0
63	Pancreatic NETs: where do we stand now?. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 361-366.	5.9	4
64	An update on gastroenteropancreatic neuroendocrine tumors. <i>Oncology</i> , 2014, 28, 749-56, 758.	0.5	45
65	Evolving Treatment Strategies for Management of Carcinoid Tumors. <i>Current Treatment Options in Oncology</i> , 2013, 14, 374-388.	3.0	10
66	Update on the Management of Unusual Neuroendocrine Tumors: Pheochromocytoma and Paraganglioma, Medullary Thyroid Cancer and Adrenocortical Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, 120-133.	2.2	37
67	Treatment of Metastatic Neuroendocrine Tumors of the Thymus with Capecitabine and Temozolomide: A Case Series. <i>Neuroendocrinology</i> , 2013, 97, 318-321.	2.5	20
68	A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2013, 20, 383-390.	3.1	32
69	A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. <i>Annals of Oncology</i> , 2012, 23, 2335-2341.	1.2	53
70	Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2012, 256, 321-325.	4.2	134
71	Incidental Detection of Pancreatic Neuroendocrine Tumors: An Analysis of Incidence and Outcomes. <i>Annals of Surgical Oncology</i> , 2012, 19, 2932-2936.	1.5	114
72	Neuroendocrine tumours of the small intestine. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 755-773.	2.4	75

#	ARTICLE	IF	CITATIONS
73	RUNX1T1. <i>Pancreas</i> , 2011, 40, 627-633.	1.1	26
74	A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. <i>Cancer Control</i> , 2011, 18, 127-137.	1.8	71
75	First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. <i>Cancer</i> , 2011, 117, 268-275.	4.1	647
76	Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. <i>World Journal of Gastroenterology</i> , 2010, 16, 2963.	3.3	104
77	Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut. <i>Neuroendocrinology</i> , 2009, 89, 471-476.	2.5	149
78	Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. <i>Human Pathology</i> , 2009, 40, 1262-1268.	2.0	126
79	Survival and Prognostic Factor Analysis in Patients With Metastatic Pancreatic Endocrine Carcinomas. <i>Pancreas</i> , 2009, 38, 255-258.	1.1	54
80	Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy. <i>Neuroendocrinology</i> , 2007, 85, 216-220.	2.5	24
81	External beam irradiation of myocardial carcinoid metastases: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 95.	0.8	5
82	Metastatic carcinoid tumor to the ovary: A clinicopathologic analysis of seventeen cases. <i>Gynecologic Oncology</i> , 2007, 106, 65-68.	1.4	58
83	Improved Outcome With Cytorreduction Versus Embolization for Symptomatic Hepatic Metastases of Carcinoid and Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2006, 13, 572-581.	1.5	211
84	Radioembolization for Metastatic Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 0, 05, .	0.2	0